Start
Protection
( dapagliflozin )
Earlier1 – 3 * * NEW EXPANDED PBS LISTING FOR T2D
( dapagliflozin / metformin HCl extended-release ) tablets
The first and only SGLT2i PBS listed for T2D patients without a glycaemic requirement : 1 – 3
• at high risk of a cardiovascular event or have cardiovascular disease
• or First Nations Australians
High risk of a CV event First Nations Australians
CV Disease
Refer to PBS Schedule for full information
SCAN FOR
FORXIGA ®
PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING . PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR BY SCANNING THE QR CODES .
SCAN FOR XIGDUO ® XR
PBS Information : FORXIGA ® : Authority Required ( STREAMLINED ): Type 2 Diabetes , Chronic Heart Failure and Chronic Kidney Disease . Refer to PBS Schedule for full Authority Required Information .
PBS Information : XIGDUO ® XR : Authority Required ( STREAMLINED ). Type 2 diabetes . Refer to PBS Schedule for full Authority Required Information .
WARNING : Life-threatening lactic acidosis can occur due to accumulation of metformin . The main risk factor is renal impairment , other risk factors include old age associated with reduced renal function and high doses of metformin above 2g per day . 2
References : 1 . FORXIGA ® Approved Product Information . 2 . XIGDUO ® XR Approved Product Information . 3 . The Pharmaceutical Benefits Scheme ( PBS ). PBS website . https :// www . pbs . gov . au . Last accessed December 2024 . FORXIGA ® and XIGDUO ® XR are registered trademarks of the AstraZeneca group of companies . Registered user AstraZeneca Pty . Ltd . ABN 54 009 682 311 . 66 Talavera Road , Macquarie Park , NSW 2113 . www . astrazeneca . com . au . For Medical Information enquiries or to report an adverse event or product quality complaint : Telephone 1800 805 342 or via https :// contactazmedical . astrazeneca . com . AU-21211A . 2686 . December 2024 .